LivaNova expands OSA care with FDA-approved aura6000 system

LivaNova LIVN recently received premarket approval from the FDA for its aura6000 system to treat adults with moderate to severe Obstructive Sleep Apnea (OSA). The system uses proximal hypoglossal nerve stimulation (p-HGNS), an advanced neurostimulation approach, to manage OSA in patients with an apnea-hypopnea index (AHI) ranging from 15 to 65 years. It is specifically intended for individuals who have not responded to, cannot tolerate or are...